Daiichi Sankyo Expects Annual Results To Improve On Higher Enhertu, Datroway Sales

AI Briefing

• – Daiichi Sankyo expects higher earnings and revenue for the full year driven by increased sales of its treatments for high blood pressure and diabetes.
• – The company's US subsidiary, Daiichi Sankyo Inc., is also benefiting from the approval of its new treatment for high cholesterol.
• – Daiichi Sankyo aims to increase its total sales of its treatments for cardiovascular diseases in the US by 10% in the current fiscal year.